Many Advanced Cancer Patients Misunderstand Treatment Intent, Studies Show

Many advanced cancer patients do not understand that their treatment is not curative. A 2012 study in the New England Journal of Medicine found that among patients with metastatic lung or colorectal cancer—cancers for which chemotherapy is not curative—69 percent and 81 percent, respectively, did not understand that their treatment would not cure them. A more recent study of 986 advanced cancer patients found that 74 percent still misperceived their treatment’s intent.

The mechanism behind this misunderstanding has been described as collusion, where both patient and physician move from prognosis to plan without acknowledging the hard truth. Patients who rated their physician’s communication as excellent were more likely to hold inaccurate beliefs about cure than those who rated it less highly.

Physicians themselves report difficulty with these conversations. Sixty percent of physicians say making survival estimates is stressful and difficult, and only 14 percent of oncologists say they would discuss hospice with a newly diagnosed metastatic patient 'now.'

Yet honest discussions do not harm patients psychologically. Research shows that patients whose physicians discussed prognosis honestly fared no worse in terms of depression, anxiety, and suicidal ideation, and fared better practically, with more advance care planning, more time at home, and earlier hospice referral. Among 179 ICU surrogate decision-makers, 93 percent said avoiding the conversation about prognosis is an unacceptable way to maintain hope.

The language used in cancer care also influences choices. Research indicates that the decision to forego treatments for supportive care can sometimes lead to longer lives with better reported quality of life. The 'time toxicity' of aggressive therapy—frequent hospital visits, clinic appointments, and imaging studies—can be as detrimental as the therapy itself to a patient’s quality of life.

Diagnostic delays are another barrier. In one case in Taiwan, a woman with a palpable breast lump faced a nearly 20-day wait for a diagnostic mammogram. After traveling to a community hospital in Taipei, clinical judgment led directly to further evaluation and timely intervention. The delay was attributed to fragmented care in large tertiary medical centers, where each step requires authorization, scheduling, and risk calculation. Smaller community hospitals with shorter decision-making chains and greater physician autonomy can act more quickly.

In lung cancer care, pathologists play a central role in reducing such delays. Early pathologist involvement enables rapid biomarker testing, helping reduce delays in initiating first-line therapy. Small or cytology-based samples require strategic selection of testing modalities to maximize actionable results. Coordination between pathology, oncology, and molecular teams improves outcomes, though inconsistent workflows remain a barrier.